Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma

被引：0
|
作者：
Samples, Laura S.
Sadrzadeh, Hossein
Frigault, Matthew J.
Jacobson, Caron Alyce
Hamadani, Mehdi
Gurumurthi, Ashwath
Strati, Paolo
Shouval, Roni
Riedell, Peter A.
Dahiya, Saurabh
Yared, Jean
Jain, Michael D.
Locke, Frederick L.
Leslie, Lori Ann
Epperla, Narendranath
Ghosh, Monalisa
Skarbnik, Alan
Hill, Brian T.
Kamdar, Manali K.
Shadman, Mazyar
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[2] Boston Univ, Med Ctr, Boston, MA USA
[3] Massachusetts Gen Hosp, Boston, MA USA
[4] Dana Farber Canc Inst, Boston, MA USA
[5] Med Coll Wisconsin, Milwaukee, WI USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY USA
[9] Univ Chicago, Med Ctr, Chicago, IL USA
[10] Stanford Canc Ctr GI Surg Oncol, Stanford, CA USA
[11] Univ Maryland, Baltimore, MD USA
[12] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[13] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[14] John Theurer Canc Ctr, Hackensack, NJ USA
[15] Ohio State Univ, Columbus, OH USA
[16] Univ Michigan, Hlth Management Res Ctr, Ann Arbor, MI USA
[17] Novant Hlth Canc Inst, Charlotte, NC USA
[18] Cleveland Clin, Cleveland, OH USA
[19] Univ Colorado Hosp, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7571
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Beyond CD19 CAR-T cells in lymphoma
    Leung, Wingchi K.
    Ayanambakkam, Adanma
    Heslop, Helen E.
    Hill, LaQuisa C.
    CURRENT OPINION IN IMMUNOLOGY, 2022, 74 : 46 - 52
  • [42] CD19 CAR T-CELL CLINICAL OUTCOME IS ASSOCIATED WITH THE GUT MICROBIOME
    不详
    CANCER DISCOVERY, 2022, 12 (05) : 1182 - 1182
  • [43] Development and Validation of a Clinical Prediction Model for the Efficacy of CD19 CAR T-Cell Therapy in DLBCL
    Xue, Bin
    Luo, Xiu
    Liu, Yifan
    Zhou, Lili
    Ye, Shiguang
    Li, Shaoguang
    Li, Ping
    Liang, Aibin
    BLOOD, 2023, 142
  • [44] CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up
    Mueller, Fabian
    Taubmann, Jule
    Bucci, Laura
    Wilhelm, Artur
    Bergmann, Christina
    Voelkl, Simon
    Aigner, Michael
    Rothe, Tobias
    Minopoulou, Ioanna
    Tur, Carlo
    Knitza, Johannes
    Kharboutli, Soraya
    Kretschmann, Sascha
    Vasova, Ingrid
    Spoerl, Silvia
    Reimann, Hannah
    Munoz, Luis
    Gerlach, Roman G.
    Schaefer, Simon
    Grieshaber-Bouyer, Ricardo
    Korganow, Anne-Sophie
    Farge-Bancel, Dominique
    Mougiakakos, Dimitrios
    Bozec, Aline
    Winkler, Thomas
    Kroenke, Gerhard
    Mackensen, Andreas
    Schett, Georg
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (08): : 687 - 700
  • [45] Lymphodepleting Chemotherapy before CD19 Directed CAR T-Cell Therapy: Are 3 Days Necessary?
    Geer, Marcus
    Kasha, Salena
    Frame, David
    Ghosh, Monalisa
    BLOOD, 2022, 140 : 3823 - 3824
  • [46] Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells
    Bishop, David C.
    Clancy, Leighton E.
    Simms, Renee
    Burgess, Jane
    Mathew, Geetha
    Moezzi, Leili
    Street, Janine A.
    Sutrave, Gaurav
    Atkins, Elissa
    McGuire, Helen M.
    Gloss, Brian S.
    Lee, Koon
    Jiang, Wei
    Maddock, Karen
    McCaughan, Georgia
    Avdic, Selmir
    Antonenas, Vicki
    'Brien, Tracey A. O.
    Shaw, Peter J.
    Irving, David O.
    Gottlieb, David J.
    Blyth, Emily
    Micklethwaite, Kenneth P.
    BLOOD, 2021, 138 (16) : 1504 - 1509
  • [47] Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia
    Phely, Laurent
    Hensen, Luca
    Faul, Christoph
    Ruff, Christer Alexander
    Schneider, Dina
    Bethge, Wolfgang Andreas
    Lengerke, Claudia
    JAMA ONCOLOGY, 2024, 10 (06) : 821 - 824
  • [48] Predictors and Implications of Renal Injury in Large Cell Lymphoma Patients Receiving CD19 CAR T Cell Therapy
    Boardman, Alexander P.
    Gutgarts, Victoria
    Flynn, Jessica R.
    Devlin, Sean M.
    Tomas, Ana Alarcon
    Fein, Joshua A.
    Slingerland, John
    Parascondola, Allison
    Lin, Richard J.
    Scordo, Michael
    Batlevi, Connie Lee
    Dahi, Parastoo B.
    Giralt, Sergio A.
    Palomba, M. Lia
    Salles, Gilles
    Nath, Karthik
    Walji, Moneeza
    De Lapuerta, Magdalena Corona
    Shah, Gunjan L.
    Perales, Miguel-Angel
    Jaffer-Sathick, Insara
    Shouval, Roni
    BLOOD, 2022, 140 : 4671 - 4672
  • [49] CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin's Lymphoma
    Xue, YuanBo
    Lai, Xun
    Li, RuiLei
    Ge, ChunLei
    Zeng, BaoZhen
    Li, Zhen
    Fu, QiaoFen
    Zhao, LiuFang
    Dong, SuWei
    Yang, JinYan
    Guo, JiYin
    Meng, QingYin
    Tan, QingHua
    Li, ZhenHui
    Ding, HaiYan
    Zhang, YanLei
    Liu, ShaoHui
    Chang, Alex H.
    Yao, Hong
    Luo, RongCheng
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [50] High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics
    Gauthier, Jordan
    Chou, Cassie
    Hirayama, Alexandre V.
    Fiorenza, Salvatore
    Sheih, Alyssa
    Pender, Barbara S.
    Tinh-Doan Phi
    Steinmetz, Rachel
    Jamieson, Abby
    Kirchmeier, Delaney R.
    Di, Henna N.
    Riddell, Stanley R.
    Maloney, David G.
    Turtle, Cameron J.
    BLOOD, 2020, 136
12345